A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.

4121Background: The optimal management of potentially resectable pancreas cancer is unknown. The high rates of local and distant failures following surgical resection highlights the need for improv...